StockNews.com Downgrades Can-Fite BioPharma (NYSE:CANF) to Sell

Can-Fite BioPharma (NYSE:CANF) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

Separately, EF Hutton Acquisition Co. I upgraded Can-Fite BioPharma to a “strong-buy” rating in a report on Wednesday, July 17th.

Can-Fite BioPharma Price Performance

NYSE CANF opened at $2.21 on Wednesday. The business has a fifty day moving average price of $2.29 and a two-hundred day moving average price of $2.51. The stock has a market capitalization of $7.82 million, a PE ratio of -1.25 and a beta of 1.41. Can-Fite BioPharma has a fifty-two week low of $1.83 and a fifty-two week high of $4.69.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC grew its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. 21.00% of the stock is owned by institutional investors and hedge funds.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.